EP4704828A2 - Inhibitoren von jun-n-terminalen kinasen (jnk1, jnk2 und/oder jnk3) und mitogenaktivierten proteinkinasen (mapk8, mapk9 und/oder mapk10) und verfahren zur verwendung davon - Google Patents

Inhibitoren von jun-n-terminalen kinasen (jnk1, jnk2 und/oder jnk3) und mitogenaktivierten proteinkinasen (mapk8, mapk9 und/oder mapk10) und verfahren zur verwendung davon

Info

Publication number
EP4704828A2
EP4704828A2 EP24797826.5A EP24797826A EP4704828A2 EP 4704828 A2 EP4704828 A2 EP 4704828A2 EP 24797826 A EP24797826 A EP 24797826A EP 4704828 A2 EP4704828 A2 EP 4704828A2
Authority
EP
European Patent Office
Prior art keywords
pyridin
carboxamide
pyrrolo
benzo
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24797826.5A
Other languages
English (en)
French (fr)
Inventor
Chandra MADASU
Stephen Palmer
Martin Matzuk
Diana MONSIVAIS
Kurt BOHREN
Zhi Tan
Jian-Yuan Li
Feng Li
Damian YOUNG
Kiran Sharma
Murugesan PALANIAPPAN
Srinivas CHAMAKURI
Ramakrishna KOMMAGANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of EP4704828A2 publication Critical patent/EP4704828A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24797826.5A 2023-04-24 2024-04-24 Inhibitoren von jun-n-terminalen kinasen (jnk1, jnk2 und/oder jnk3) und mitogenaktivierten proteinkinasen (mapk8, mapk9 und/oder mapk10) und verfahren zur verwendung davon Pending EP4704828A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363461485P 2023-04-24 2023-04-24
PCT/US2024/025997 WO2024226609A2 (en) 2023-04-24 2024-04-24 Inhibitors of jun n-terminal kinases (jnk1, jnk2, and/or jnk3) and mitogen-activated protein kinases (mapk8, mapk9, and/or mapk10) and methods of using same

Publications (1)

Publication Number Publication Date
EP4704828A2 true EP4704828A2 (de) 2026-03-11

Family

ID=93257454

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24797826.5A Pending EP4704828A2 (de) 2023-04-24 2024-04-24 Inhibitoren von jun-n-terminalen kinasen (jnk1, jnk2 und/oder jnk3) und mitogenaktivierten proteinkinasen (mapk8, mapk9 und/oder mapk10) und verfahren zur verwendung davon

Country Status (7)

Country Link
EP (1) EP4704828A2 (de)
KR (1) KR20260025078A (de)
CN (1) CN121368479A (de)
AU (1) AU2024262149A1 (de)
IL (1) IL324206A (de)
MX (1) MX2025012789A (de)
WO (1) WO2024226609A2 (de)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR046078A1 (es) * 2003-08-06 2005-11-23 Senomyx Inc Nuevos sabores, modificadores de sabores, sustancias gustativas, mejoradores de gusto, sustancias gustativas y/o mejoradoras del gusto umani o dulce y uso de los mismos.

Also Published As

Publication number Publication date
WO2024226609A3 (en) 2025-03-27
IL324206A (en) 2025-12-01
KR20260025078A (ko) 2026-02-23
WO2024226609A2 (en) 2024-10-31
MX2025012789A (es) 2026-02-03
AU2024262149A1 (en) 2025-12-11
CN121368479A (zh) 2026-01-20

Similar Documents

Publication Publication Date Title
US8394802B2 (en) 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases
US11207301B2 (en) Sphingosine 1 phosphate receptor agonists for neuroprotection
KR101718596B1 (ko) 티에닐[3,2-d]피리미딘-4-온 화합물, 그 제조방법, 약물조성물 및 용도
WO2002026743A1 (en) Novel pyridazine compounds for the treatment of diabetes
US20250276955A1 (en) Coronavirus main protease inhibitors and methods using same
US20250312345A1 (en) Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use
US20260049077A1 (en) Neurotrophic Receptor Tyrosine Kinase (NTRK) Inhibitors and Methods Using Same
EP4704828A2 (de) Inhibitoren von jun-n-terminalen kinasen (jnk1, jnk2 und/oder jnk3) und mitogenaktivierten proteinkinasen (mapk8, mapk9 und/oder mapk10) und verfahren zur verwendung davon
EP3983391A1 (de) Acetyl-coa-synthetase 2-(acss2)-inhibitoren und diese verwendende verfahren
US20240158355A1 (en) Bet subfamily inhibitors and methods using same
US20220193080A1 (en) Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor
US20220267308A1 (en) Modulators of Excitatory Amino Acid Transporters and Methods Using Same
US20260085063A1 (en) Benzamide compounds and methods of use thereof
WO2025217249A1 (en) Methods for treating endometriosis and/or other ovary-related diseases and for monitoring treatment
US20250304550A1 (en) Bromodomain and extra-terminal (bet) subfamily bromodomain 1 (bd1) selective inhibitors and methods using same
US20260125399A1 (en) Substituted Pyrazolo[3,4-b]pyridine Compounds and Methods of Use Thereof
US20240092759A1 (en) Non-Covalent Inhibitors of the Main Protease of SARS-CoV-2 and Methods of Use
WO2025106722A1 (en) Inhibitors of stk33, ret, clk, and/or related kinases and methods using same
WO2025227071A1 (en) Methods and compositions for treating heart failure and liver disease
US20220388980A1 (en) Quinoline inhibitors of rad52 and methods of use
EP4642451A2 (de) N-myristoyltransferasehemmer und verfahren zur verwendung
US20230399303A1 (en) Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same
WO2025155752A1 (en) Antimetastatic galpha 12 inhibitors and methods of use thereof
WO2025240386A1 (en) Allosteric agonists and positive allosteric modulators of glucagon-like peptide 1 receptor
HK40125992A (zh) 神经营养受体酪氨酸激酶(ntrk)抑制剂及其使用方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251124

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR